Abstract
Purpose
Fine-needle aspiration (FNA) with cytologic evaluation is the most reliable tool for malignancy prediction in thyroid nodules, but cytologic diagnosis remains indeterminate for 12–18 % of nodules. BRAF V600E mutation has been reported to show a high specificity for malignant thyroid nodules and the use of this marker to refine indeterminate FNA cytology results may be a useful diagnostic adjunctive tool in the pre-operative evaluation of thyroid nodules. The aim of this study was to estimate the prevalence of BRAF exon 15 mutation (V600E) and its clinical value as a diagnostic tool in a series of thyroid nodules with indeterminate cytology from an area of borderline iodine deficiency.
Subjects and methods
One hundred and fifty-three thyroid samples obtained by FNA of thyroid nodules from 151 patients were subjected to the analysis of BRAF V600E mutation by direct sequencing. In the study 54 nodules with indeterminate cytology, 56 benign and 43 malignant thyroid nodules were included.
Results
V600E BRAF gene mutation was demonstrated in 19/43 malignant nodules, in 0/56 benign nodules and in only 1/54 indeterminate nodules that, after histology, turned out to be at a papillary thyroid carcinoma.
Conclusions
The application of BRAF exon 15 analysis showed limitations when applied to discriminate thyroid nodules with indeterminate cytology if wild-type BRAF is found, and there is no role for avoiding diagnostic thyroid surgery.
Similar content being viewed by others
References
Tonacchera M, Pinchera A, Vitti P (2010) Assessment of nodular goitre. Best Pract Res Clin Endocrinol Metab 24:51–61. doi:10.1016/j
Kang HW, No JH, Chung JH, Min YK, Lee MS, Lee MK, Yang JH, Kim KW (2004) Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas. Thyroid 14:29–33. doi:10.1186/1471-2482-9-12
Sherman SI (2003) Thyroid carcinoma. Lancet 361:501–511. doi:10.1016/s0140-6736(03)12488-9
Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedüs L, Vitti P, AACE/AME/ETA Task Force on Thyroid Nodules (2010) American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. Endocr Pract 16:468–475. doi:10.4158/10024.GL
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214. doi:10.1089/thy.2009.0110
Tan GH, Gharib H (1997) Thyroid incidentalomas: management approaches to non-palpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 126:226–231. doi:10.7326/0003-4819-126-3-199702010-00009
Rago T, Chiovato L, Aghini-Lombardi F, Grasso L, Pinchera A, Vitti P (2001) Non-palpable thyroid nodules in a borderline iodine-sufficient area: detection by ultrasonography and follow-up. J Endocrinol Invest 24:770–776. doi:10.1007/BF03343926
Rago T, Di Coscio G, Basolo F, Scutari M, Elisei R, Berti P, Miccoli P, Romani R, Faviana P, Pinchera A, Vitti P (2006) Combined clinical, thyroid ultrasounds, and cytological features help to predict thyroid malignancy in follicular and Hurtle cell thyroid lesions: results from a series of 505 consecutive patients. Clin Endocrinol 66:15–20. doi:10.1111/j.1365-2265.2006.02677.x
Gharib H (1994) Fine-needle aspiration biopsy of the thyroid nodules: advantages, limitations and effect. Mayo Clin Proc 69:44–49. doi:10.1016/S0025-6196(12)61611-5
Rago T, Fiore E, Scutari M, Santini F, Di Coscio G, Romani R, Piaggi P, Ugolini C, Basolo F, Miccoli P, Pinchera A, Vitti P (2010) Male sex, single nodularity, and young age are associated with the risk of finding a papillary thyroid cancer on fine-needle aspiration cytology in a large series of patients with nodular thyroid disease. Eur J Endocrinol 162:763–770. doi:10.1530/EJE-09-0895
Smith J, Cheifetz RE, Schneidereit N, Berean K, Thomson T (2005) Can accurately predict benign follicular nodules? Am J Surg 189:592–595. doi:10.1016/j.amjsurg.2005.01.028
DeMay RM (2000) Follicular lesions of the thyroid. W(h)ither follicular carcinoma? Am J Clin Pathol 114:681–683
Greaves TS, Olvera M, Florentine BD, Raza AS, Cobb CJ, Tsao-Wei DD, Groshen S, Singer P, Lopresti J, Martin SE (2000) Follicular lesions of thyroid: a 5 year fine-needle aspiration experience. Cancer 90:335–341
Carling T, Udelsman R (2005) Follicular neoplasm of the thyroid: what to recommend. Thyroid 15:583–587. doi:10.1089/thy.2005.15.583
Baloch ZW, Fleisher S, Livolsi VA, Gupta PK (2001) Diagnosis of ‘follicular neoplasm’: a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol 26:41–44. doi:10.1002/dc.10043
Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, Vielh P, DeMay RM, Sidawy MK, Frable WJ (2008) Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 36:425–434. doi:10.1002/dc.20830
Faquin WC, Baloch ZW (2010) Fine-needle aspiration of follicular patterned lesions of the thyroid: diagnosis, management, and follow-up according to National Cancer Institute (NCI) recommendations. Diagn Cytopathol 38:731–739. doi:10.1002/dc.21292
Nardi F, Basolo F, Crescenzi A, Fadda G, Frasoldati A, Orlandi F, Palombini L, Papini E, Zini M, Pontecorvi A, Vitti P (2014) Italian consensus for the classification and reporting of thyroid cytology. J Endocrinol Invest 37:593–599. doi:10.1007/s40618-014-0062-0
Eszlinger M, Paschke R (2010) Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol Cell Endocrinol 322:29–37. doi:10.1016/j.mce.2010.01.010
Tallini G, Asa SL (2001) RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol 8:345–354. doi:10.1186/1756-6614-4-5
Kondo T, Ezzat S, Asa SL (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292–306. doi:10.1038/nrc1836
Xing M (2005) BRAF mutation in thyroid cancer. Endocr Rel Cancer 12:245–262. doi:10.1677/erc.1.0978
Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE (2006) Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30:216–222
Namba H, Rubin SA, Fagin JA (1990) Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4:1474–1479. doi:10.1210/mend-4-10-1474
Agate L, Lorusso L, Elisei R (2012) New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. J Endocrinol Invest 35(6 Suppl):3–9
Witt RL, Ferris RL, Pribitkin EA, Sherman SI, Steward DL, Nikiforov YE (2013) Diagnosis and management of differentiated thyroid cancer using molecular biology. Laryngoscope 123:1059–1064. doi:10.1002/lary.23838
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954. doi:10.1038/nature00766
Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R (2004) Cancer Genome Project, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855–867. doi:10.1016/S0092-8674(04)00215-6
Baloch ZW, LiVolsi VA (2004) Fine needle aspiration of thyroid nodules: past, present and future. Endocr Pract 10:234–241. doi:10.4158/EP.10.3.234
Tonacchera M, Agretti P, Rago T, De Marco G, Niccolai F, Molinaro A, Scutari M, Candelieri A, Conforti D, Musmanno R, Di Coscio G, Basolo F, Iacconi P, Miccoli P, Pinchera A, Vitti P (2012) Genetic markers to discriminate benign and malignant thyroid nodules with undetermined cytology in an area of borderline iodine deficiency. J Endocrinol Invest 35:754–759
Johnson SJ, Hardy SA, Roberts C, Bourn D, Mallick U, Perros P (2014) Pilot of BRAF mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology. Cytopathology 25:146–154. doi:10.1111/cyt.12125
Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN (2009) Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 94:2092–2098. doi:10.1210/jc.2009-0247
Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB, Haugen BR (2012) Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 367:705–715. doi:10.1056/NEJMoa1203208
Hodak SP, Rosenthal DS, American Thyroid Association Clinical Affairs Committee (2013) Information for clinicians: commercially available molecular diagnosis testing in the evaluation of thyroid nodule fine-needle aspiration specimens. Thyroid 23:131–134. doi:10.1089/thy.2012.0320
Marchetti I, Iervasi G, Mazzanti CM, Lessi F, Tomei S, Naccarato AG, Aretini P, Alberti B, Di Coscio G, Bevilacqua G (2012) Detection of the BRAF(V600E) mutation in fine needle aspiration cytology of thyroid papillary microcarcinoma cells selected by manual macrodissection: an easy tool to improve the preoperative diagnosis. Thyroid 22:292–298. doi:10.1089/thy.2011.0107
Marchetti I, Lessi F, Mazzanti CM, Bertacca G, Elisei R, Coscio GD, Pinchera A, Bevilacqua G (2009) A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid 19:837–842. doi:10.1089/thy.2009.0074
Seo JY, Kim EK, Kwak JY (2014) Additional BRAF mutation analysis may have additional diagnostic value in thyroid nodules with “suspicious for malignant” cytology alone even when the nodules do not show suspicious US features. Endocrine [Epub ahead of print]. doi:10.1007/s12020-013-0150-5
Zatelli MC, Trasforini G, Leoni S, Frigato G, Buratto M, Tagliati F, Rossi R, Cavazzini L, Roti E, degli Uberti EC (2009) BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol 161:467–473. doi:10.1530/EJE-09-0353
Acknowledgments
We are grateful to Ministero dell’ Università e della Ricerca Scientifica (MURST) and Ministero della Sanità for funding.
Conflict of interest
The authors declare that they have no actual or potential conflict of interest.
Ethical standards
The study was approved by the local ethical committee and informed consent was obtained from all subjects.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Agretti, P., Niccolai, F., Rago, T. et al. BRAF mutation analysis in thyroid nodules with indeterminate cytology: our experience on surgical management of patients with thyroid nodules from an area of borderline iodine deficiency. J Endocrinol Invest 37, 1009–1014 (2014). https://doi.org/10.1007/s40618-014-0166-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-014-0166-6